







There are so many ways to talk about mutations that are not that common — uncommon, rare, non-classical, acquired, atypical — how do we best explain to patients that these all mean the same things and guide them to the questions they need to ask their doctors?











Л



5





















10

Can you use osimertinib for the uncommon EGFR mutations? *Maybe*

The use of osimertinib to treat uncommon EGFR mutations is off-label, but may be preferred in selected uncommon mutations (e.g., L861Q) or if needed to treat brain metastases

(30-75)

(45-94)

The UNICORN study evaluated osimertinib for uncommon mutations
Response rate/progress free survival ware not the common mutations.

11

L861Q

- Response rate/progress free survival were not the same across all mutations
 Novel agents are being evaluated in clinical trials for the uncommon EGFR mutations
- | Patient Subgroup | Number of | Response Rate | Progression-free Sun/val | (95% C) | (95% C) | (85 months | (45-74) | (73-13.5) | (45-74) | (73-13.5) | (73-13.5) |


(6.9–NA) 15.7 months

(8.9-18.8)











Double Mutant vs. Triple Mutant Ac What we know about	
EGFRm + EGFR C797X "Double Mutant" Acquired resistance to first-line osimertinib Reported sensitivity to 1 st generation EGFR TKIs (ge erlotinib)	ffitinib,
2 EGFRm + EGFR T790M + EGFR C797X "Triple Mu - Acquired resistance to sequential 1st and 3st general kinase inhibitors - Resistant to all approved EGFR tyrosine kinase inhibit protein - 4th Generation EGFR tyrosine kinase inhibitors in co	ation EGFR tyrosine pitors if in same EGFR
In trans-EGFR T790M + EGFR C797X mutations occur on separate alleles.	Leonetti A. et al. 8r / Cancer, 2019-121/9):725-737.


Compound	Del19	L858R	Del19/ T790M	L858R/ T790M	Del19/ C797S	L858R/ C797S	Triple Mutant	Other	CNS?	Status
BLU-945	-	х	х	Х	?	Х	х		-	Phase 1/2 (NCT04862780)
BLU-525	х	х	-	-	Х	Х	х		Х	Preclinical
BDTX-1535	Х	х	-	-	Х	Х	x	*Uncommon	Х	Phase 1 (NCT05256290)
HE-349	х	х	Х	х	х	Х	x		Х	Preclinical
1002	Х	х	х	Х	Х	Х	х		Х	Phase 1/2 (NCT05552781)
BAY 1927088	х	х			х	х		Ex20ins		Phase 1 (NCT05099172)
IN-A02	Х	Х	Х	Х	x		х		х	Phase 1/2 (NCT05394831)
BT-176	х	Х	Х		х	х	х		х	Phase 1/2 (NCT04820023)






























Biomarker testing—takes a relay team! Tissue biopsy Bronchoscopy CTguided needle biopsy Pathology Molecular lab Oncology

